8 completed, 3 terminated, 1 withdrawn. 12 Phase 1, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 12 | Completed 8, Terminated 3, Withdrawn 1 |
| Phase 2 | 6 | Completed 4, Terminated 2 |
Follow PLX3397: new trials by email Literature Review of PLX3397 trials Research Report on PLX3397
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of Safety and Activity of an Anti-PDL1 Antibody (DURVALUMAB) Combined With CSF-1R TKI (PEXIDARTINIB) in Patients With Metastatic/Advanced Pancreatic or Colorectal Cancers Pexidartinib, Durvalumab - Colorectal Cancer, Pancreatic Cancer | Phase 1 | Completed | Centre Leon Berard | 48 | 2016-06-01 | 2021-09-05 |
| PLX3397 Plus Sirolimus in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors PLX3397, sirolimus - Sarcoma, Malignant Peripheral Nerve Sheath Tumors | Phase 1 / Phase 2 | Terminated | Gulam Manji | 39 | 2015-11-04 | 2025-03-21 |
| A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors PLX3397, Pembrolizumab - Melanoma, Non-small Cell Lung Cancer | Phase 1 / Phase 2 | Terminated | Daiichi Sankyo | 78 | 2015-07-02 | 2020-03-05 |
| PLX3397, Radiation Therapy, and Antihormone Therapy in Treating Patients With Intermediate- or High-Risk Prostate Cancer Antiandrogen Therapy, Laboratory Biomarker Analysis, Multitargeted Tyrosine Kinase Inhibitor PLX3397 - Stage I Prostate Adenocarcinoma, Stage II Prostate Adenocarcinoma | Phase 1 | Completed | Barbara Ann Karmanos Cancer Institute | 8 | 2015-06-01 | 2020-10-06 |
| CGT9486 (Formerly Known as PLX9486) as a Single Agent and in Combination With PLX3397 (Pexidartinib) or Sunitinib in Participants With Advanced Solid Tumors CGT9486, Pexidartinib, Sunitinib - Gastrointestinal Stromal Tumors | Phase 1 / Phase 2 | Completed | Cogent Biosciences, Inc. | 51 | 2015-03-06 | 2025-02-14 |
| A Phase 1b Open Label, Dose Escalation Study of PLX3397 in Combination With Vemurafenib in V600-mutated BRAF Melanoma PLX3397, vemurafenib - V600-mutated BRAF Unresectable Melanoma, V600-mutated BRAF Metastatic Melanoma | Phase 1 | Terminated | Daiichi Sankyo | 13 | 2013-11-05 | 2020-05-28 |
| A Phase 1b/2 Study of PLX3397 + Radiation Therapy + Temozolomide in Patients With Newly Diagnosed Glioblastoma PLX3397, Radiation Therapy, Temozolomide - Patients With Newly Diagnosed Glioblastoma | Phase 1 / Phase 2 | Completed | Daiichi Sankyo | 65 | 2013-07-18 | 2020-06-30 |
| Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer PLX3397, Eribulin - Metastatic Breast Cancer | Phase 1 / Phase 2 | Completed | Hope Rugo, MD | 67 | 2012-07-12 | 2020-07-17 |
| Safety Study of PLX3397 and Paclitaxel in Patients With Advanced Solid Tumors PLX3397, Paclitaxel - Solid Tumors | Phase 1 | Completed | Daiichi Sankyo | 74 | 2012-05-01 | 2020-07-16 |
| Phase 1/2 Safety and Efficacy of PLX3397 in Adults With Relapsed or Refractory Acute Myeloid Leukemia (AML) PLX3397 - Acute Myeloid Leukemia | Phase 1 / Phase 2 | Completed | Daiichi Sankyo | 90 | 2011-11-21 | 2020-03-02 |
| Safety, Pharmacokinetic (PK), Pharmcodynamic (PD), and Drug-Drug Interaction of PLX3397 in Patients With Rheumatoid Arthritis Who Are Receiving Methotrexate PLX3397 - Rheumatoid Arthritis | Phase 1 | Withdrawn | Plexxikon | 2010-05-01 | 2015-03-17 | |
| Safety Study of PLX108-01 in Patients With Solid Tumors PLX3397 - Solid Tumor | Phase 1 | Completed | Daiichi Sankyo | 132 | 2009-10-01 | 2022-01-04 |
Gastrointestinal Stromal Tumors (2) · Neoplasm Metastasis (2) · Arthritis, Rheumatoid (1) · Breast Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Colorectal Neoplasms (1) · Glioblastoma (1) · Leukemia, Myeloid, Acute (1) · Melanoma (1) · Neoplasms (1) · Neurofibrosarcoma (1) · Ovarian Neoplasms (1) · Pancreatic Neoplasms (1) · Recurrence (1) · Sarcoma (1)
Daiichi Sankyo (6) · Barbara Ann Karmanos Cancer Institute (1) · Centre Leon Berard (1) · Cogent Biosciences, Inc. (1) · Gulam Manji (1) · Hope Rugo, MD (1) · Plexxikon (1)
United States (11) · France (2) · Germany (1)
Alexander Perl, MD (1) · Catherine Smith, MD (1) · Elisabeth I. Heath, M.D. (1) · Eunice Wang, MD (1) · Gail Roboz, MD (1) · Gulam A. Manji, MD (1) · Hope S. Rugo, MD (1) · Jessica Sachs, MD (1) · John Pagel, MD, PhD (1) · Mark Levis, MD, PhD (1) · Olga Frankfurt, MD (1) · Richard Stone, MD (1)
PMID 24101040, PMID 24552317, PMID 26222558, PMID 32330242, PMID 33289960, PMID 34236401, PMID 34321280, PMID 34716196, PMID 38266104
2015 (1), P30CA022453 (1)